These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34909720)

  • 1. Psoriasis Severity, Comorbidities, and Treatment Response Differ among Geographic Regions in the United States.
    Enos CW; O'Connell KA; Harrison RW; McLean RR; Dube B; Van Voorhees AS
    JID Innov; 2021 Jun; 1(2):100025. PubMed ID: 34909720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry.
    Lebwohl M; Strober B; Schrader A; Li AH; Eckmann T; Zhu B; Malatestinic WN; Birt J; Feely M; Blauvelt A
    Drugs Real World Outcomes; 2024 Sep; 11(3):451-464. PubMed ID: 38914857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Geographic Patterns in Psoriasis: An Observational Study of CorEvitas Psoriasis Registry.
    Enos CW; O'Connell KA; Harrison RW; McLean RR; Dube B; Van Voorhees AS
    J Psoriasis Psoriatic Arthritis; 2022 Jul; 7(3):122-131. PubMed ID: 39296532
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
    Lockshin B; Cronin A; Harrison RW; McLean RR; Anatale-Tardiff L; Burge R; Zhu B; Malatestinic WN; Atiya B; Murage MJ; Gallo G; Strober B; Van Voorhees A
    Dermatol Ther; 2021 Mar; 34(2):e14808. PubMed ID: 33491259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS).
    Marcombes C; Penso L; Weill A; Dray-Spira R; Zureik M; Sbidian E
    Br J Dermatol; 2023 Oct; 189(5):561-568. PubMed ID: 37479503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry.
    Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
    J Am Acad Dermatol; 2022 Jan; 86(1):68-76. PubMed ID: 34256035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry.
    Yu C; Wang G; Burge RT; Ye E; Dou G; Li J; Harrison RW; McLean RR; Kerti SJ; Bagel J
    Dermatol Ther (Heidelb); 2023 Jan; 13(1):187-206. PubMed ID: 36385699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities.
    Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
    J Psoriasis Psoriatic Arthritis; 2023 Jan; 8(1):7-10. PubMed ID: 39296950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Persistence and Adherence Among Patients With Psoriatic Arthritis Who Initiated Targeted Immune Modulators in the US: A Retrospective Cohort Study.
    Walsh JA; Cai Q; Lin I; Pericone CD; Chakravarty SD
    Adv Ther; 2021 May; 38(5):2353-2364. PubMed ID: 33759081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiometabolic multimorbidity is common among patients with psoriasis and is associated with poorer outcomes compared to those without comorbidity.
    Enos CW; Ramos VL; McLean RR; Lin TC; Foster N; Dube B; Van Voorhees AS
    J Dermatolog Treat; 2022 Nov; 33(7):2975-2982. PubMed ID: 35737885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry.
    Strober B; Greenberg JD; Karki C; Mason M; Guo N; Hur P; Zhao Y; Herrera V; Lin F; Lebwohl M
    BMJ Open; 2019 Apr; 9(4):e027535. PubMed ID: 31005939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.
    Ogdie A; Palmer JL; Greenberg J; Curtis JR; Harrold LR; Solomon DH; Kavanaugh A; Kremer JM; Mease PJ
    J Rheumatol; 2019 May; 46(5):475-482. PubMed ID: 30647182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
    Strober B; Karki C; Mason M; Guo N; Holmgren SH; Greenberg JD; Lebwohl M
    J Am Acad Dermatol; 2018 Feb; 78(2):323-332. PubMed ID: 29051036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of the Product of the 5-Point Investigator's Global Assessment and Body Surface Area (IGA × BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis.
    Gottlieb AB; Germino R; Herrera V; Meng X; Merola JF
    Dermatology; 2019; 235(4):348-354. PubMed ID: 31141807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study.
    Kridin K; Abdelghaffar M; Mruwat N; Ludwig RJ; Thaçi D
    J Eur Acad Dermatol Venereol; 2024 Feb; 38(2):315-324. PubMed ID: 37730962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
    Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
    Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.
    Mease PJ; Karki C; Palmer JB; Etzel CJ; Kavanaugh A; Ritchlin CT; Malley W; Herrera V; Tran M; Greenberg JD
    J Rheumatol; 2017 Aug; 44(8):1151-1158. PubMed ID: 28620063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL).
    Seneschal J; Lacour JP; Bewley A; Faurby M; Paul C; Pellacani G; De Simone C; Horne L; Sohrt A; Augustin M; Hammond E; Reich K
    J Eur Acad Dermatol Venereol; 2020 Nov; 34(11):2566-2573. PubMed ID: 32364296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.